Literature DB >> 20711118

An immunohistochemical study of androgen receptor in carcinoma arising in pleomorphic salivary adenoma.

Bassel Tarakji1, Omar Kujan.   

Abstract

UNLABELLED: Carcinoma originating within a pre-existing in pleomorphic adenoma is well-known phenomena and is occasionally debated in the field of surgical pathology. The use of the hormone treatment in salivary gland cancers is controversial. The management of patients who show positive reactivity to androgen receptor in prostate carcinomas has guided the researchers to assess the expression of this receptor in a variety of other tumors, including those arising in the salivary glands and particularly in carcinoma ex pleomorphic adenoma.
OBJECTIVE: Our study aimed to characterize alteration in the immunohistochemical expression of androgen receptor in the tumor cells of carcinoma arising in pleomorphic adenoma. STUDY
DESIGN: 20 cases of carcinoma arising in pleomorphic adenoma (undifferentiated and adenocarcinoma types) were examined.
RESULTS: The results showed that 10 (50%) of 20 cases had negative nuclear staining, whereas 10 (50%) of 20 cases had positive nuclear staining for androgen receptor.
CONCLUSION: Our data suggest that carcinoma arising in pleomorphic adenoma may be dependent on endocrine function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20711118     DOI: 10.4317/medoral.16.e330

Source DB:  PubMed          Journal:  Med Oral Patol Oral Cir Bucal        ISSN: 1698-4447


  2 in total

Review 1.  Biological roles and clinical significance of estrogen and androgen receptors in head and neck cancers.

Authors:  Chunhong Qin; Yan Lu; Huimin Zhang; Zhe Zhang; Wei Xu; Shuxin Wen; Wei Gao; Yongyan Wu
Journal:  J Cancer       Date:  2022-04-04       Impact factor: 4.478

2.  Hormone dependent metastatic salivary gland carcinoma: a case report.

Authors:  Abed Agbarya; Salem Billan; Haitam Nasrallah; Addie Dvir; Lior Soussan-Gutman; Orit Kaidar-Person
Journal:  Springerplus       Date:  2014-07-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.